Illumina saw the highest growth of 2.12% in patent filings and 1.59% in grants in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 2.12% and grants by 1.59%. GlobalData’s DataBook provides a comprehensive analysis of Illumina‘s patent filings and grants. Buy the databook here.
Illumina has been focused on protecting inventions in United States(US) with 114 publications in Q2 2024
The United States(US) Patent Office dominates the patent filings and grants with nearly 33% filings and 29% grants. The United States(US), World Intellectual Property Organization(WIPO), China(CN), and European Patent Office(EPO) patent Office are among the top ten patent offices where Illumina is filings its patents. Among the top granted patent authorities, Illumina has 29% of its grants in United States(US), 11% in European Patent Office(EPO) and 9% in China(CN).
Thermo Fisher Scientific and Roche could be the strongest competitors for Illumina
Patents related to industrial automation and genomics lead Illumina's portfolio
Illumina has the highest number of patents in industrial automation followed by, genomics and machine learning. For industrial automation, nearly 31% of patents were filed and 30% of patents were granted in Q2 2024.
Mos micro (mpu, mcu & dsp) related patents lead Illumina portfolio followed by semiconductor products, and image management
Illumina has highest number of patents in mos micro (mpu, mcu & dsp) followed by semiconductor products, image management, healthcare it, and dyes and pigments. For mos micro (mpu, mcu & dsp), nearly 8% of patents were filed and 10% of patents were granted in Q2 2024.
For comprehensive analysis of Illumina's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.